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ABstRACt
The term leishmaniasis comprises a group of diseases caused by different species of a protozoon called Leishmania. 
Leishmaniasis is found worldwide, and is considered to be endemic in 88 countries. There are three main clinical forms 
of leishmaniasis: visceral leishmaniasis, cutaneous leishmaniasis and mucocutaneous leishmaniasis. Exclusive involve-
ment of the mucosa is very rare. We present a series of three cases of mucosal leishmaniasis located in the oral cavity. 
The fact that all three cases were recorded in Spain (an area where L. infantum is endemic), suggests that the latter was 
the causal agent. The only manifestation of leishmaniasis disease in the described cases was the appearance of an oral 
lesion. Treatment was provided in the form of meglumine antimoniate in two patients, with a favorable response. One 
of the patients left the hospital after diagnosis, without receiving treatment, and the subsequent course is not known. A 
review is made of the literature on the subject.
Key words: Mucosal leishmaniasis, leishmania infantum, mediterranean leishmaniasis.
REsUMEN
El término leishmaniasis comprende un grupo de enfermedades causadas por diferentes especies de un protozoo lla-
mado Leishmania. La leishmaniasis se produce en todo el mundo, considerándose endémica en 88 países. Existen tres 
formas clínicas principales de leishmaniasis: leishmaniasis visceral, leishmaniasis cutánea y leishmaniasis mucocutánea. 
La afectación de la mucosa, de manera exclusiva, por la Leishmania es muy rara. Presentamos una serie de tres casos 
de leishmaniasis mucosa localizados en la cavidad oral. El hecho de que todos los casos se produjeran en España, área 
endémica de L infantum, nos hace presuponer que éste fue el agente causal. La única manifestación de enfermedad de 
leishmaniasis en los casos descritos, fue la aparición de una lesión oral. Se administró tratamiento con antimoniato de 
meglumina en dos de ellos, respondiendo favorablemente. Uno de los pacientes abandonó el hospital tras el diagnóstico 
sin recibir tratamiento y se desconoce la evolución.  Realizamos también una revisión de la literatura.
Palabras clave: Leishmaniasis mucosa, leishmania infantum, leishmaniasis mediterránea.
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INtRODUCtION
Leishmaniasis, caused by a heterogeneous group of proto-
zoan parasites belonging to the genus Leishmania, produces 
a number of clinical syndromes (1-7). Rodents and canines 
(both wild and domestic) constitute the natural reservoir of 
Leishmania, which is transmitted from animals to humans, 
and occasionally from one human to another, by means of 
the female mosquito (Phlebotomus spp. in the Old World 
and Lutzomyia spp. in the Americas)(2,3,5,6,8,9). The mos-
quito sucks the blood of humans or mammals, containing 
the protozoon in its amastigote form (lacking a flagellum). 
Once within the intestine of  the mosquito, the parasite 
transforms into a promastigote (equipped with a flagellum), 
and reproduces as such (5,8,10). From the intestine of the 
mosquito, the protozoon then migrates to the esophagus, 
where it is expelled into the skin of the host when the insect 
bites - followed by invasion of the bloodstream and different 
tissues (5,8,10). The promastigotes are phagocytosed by 
the macrophages of  the host reticuloendothelial system, 
where they lose the flagellum and once again transform 
into amastigotes. When the infected cells are destroyed, 
the parasite infects new cells and thus spreads throughout 
the body (5,8,10).
Leishmaniasis is found throughout the world, except in 
Australia and the Antarctic, and is considered to be ende-
mic in 88 countries (1,5,10). Although the disease manifests 
mainly in such endemic areas, people visiting such zones 
can become infected after less than a single week of expo-
sure (11). It is estimated that 350 million people are at risk 
of contracting the illness, and its prevalence is 12 million 
infected individuals worldwide - with a global incidence of 
1.5-2 million new cases per year (1,2,5,8,10). Leishmaniasis 
is responsible for approximately 70,000 to 80,000 deaths a 
year (8,10).
Over 20 different species of Leishmania have been descri-
bed (3,5,8). There are three clinical forms of leishmaniasis: 
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), 
and mucocutaneous leishmaniasis (MCL)(6,10). Each of 
them is generally associated with certain species and con-
crete geographical settings. Thus, CL in the Americas is 
caused by L. mexicana, L. amazonensis, L. braziliensis, L. 
panamensis, L. peruviana and L. guyanensis, while in the 
Old World it is caused by L. tropica, L. major, L. aethiopica 
and L. infantum. In turn, VL is caused by L. donovani in 
India, Asia and Africa, while in the Mediterranean, North 
Africa, Central and Southeast Asia and South America it 
is caused by L. infantum or L. chagasi. MCL, which is the 
least frequent clinical form of the disease, is caused by L. 
braziliensis in the Americas, while and in the Old World L. 
aethiopica is responsible (1-4,8-10). However, it is increa-
singly clear that species commonly associated with VL can 
produce skin or mucosal lesions, and vice versa.
Exclusive involvement of the mucosa is very rare. We present 
a series of three cases of mucosal leishmaniasis located in 
the oral cavity.
CLINICAL CAsEs
Table 1 describes the characteristics of the three patients 
presented in this study (table 1).
Case 1. A 70-year-old male was referred to the maxillofacial 
surgery unit for evaluation of an ulcerated and painful lesion 
measuring 2 cm in diameter, located in the anterior region 
of the floor of the mouth, around the outlet of the right 
Wharton’s duct. The lesion was indurated and presented 
irregular margins. As personal antecedents, the patient 
had type 2 diabetes mellitus subjected to treatment with 
oral antidiabetics, and interstitial desquamative pneumo-
pathy treated with low-dose corticoids. He had undergone 
prostatectomy, and presented a history of  deep venous 
thrombosis and relapsing orchiepididymitis. The patient was 
HIV-negative. A biopsy of the lesion was obtained under 
local anesthesia. The histological study revealed epithelium 
with a chronic inflammatory infiltrate mainly composed of 
plasma cells and histiocytes, with a cytoplasm invaded by 
Leishmania parasites. Abdominal ultrasound was subse-
quently performed, revealing no alterations, and a peripheral 
mononuclear cell culture proved negative. A bone marrow 
biopsy showed no alterations. Both the laboratory test and 
hematometric findings proved normal. Immunofluorescence 
showed the Leishmania IgG antibody titer to be 1:320.
The condition was classified as mucosal leishmaniasis, and 
treatment was started with meglumine antimoniate (Glu-
cantime®) at a dose of 20 mg/kg/day, during 28 days - with 
gradual disappearance of the lesion. No adverse effects of 
treatment were observed. After 10 years of follow-up, the 
patient showed no signs of relapse.
Case 2. A 41-year-old male presented with a painful ulcer 
measuring 3 cm in diameter on the right cheek mucosa (Fig. 
1). The personal history included HIV infection for the pre-
vious 25 years, with criteria of AIDS disease (stage C3). No 
antiretroviral therapy was being provided upon personal re-
quest by the patient, who was an ex-intravenous drug abuser 
with hepatitis C infection and tuberculosis two years before. 
The histopathological study of the biopsy revealed leishma-
niasis with superficial Candida albicans coinfection. The 
lymphocyte subpopulation counts were as follows: CD4: 170 
cells/mm3; CD8: 865 cells/mm3; CD4/CD8: 0.20. The HIV 
viral load was 160,000 copies/ml. Abdominal ultrasound 
and a bone marrow aspirate proved normal. The condition 
was classified as mucosal leishmaniasis, and treatment was 
started with antiretrovirals (lamivudine 150 mg / zidovudine 
300 mg (Combivir®) and nevirapine 200 mg (Viramune®)) 
and meglumine antimoniate (Glucantime®) 20 mg/kg/day. 
One month after treatment, the patient developed daily 
vomiting, asthenia, anorexia, febrile sensation and pruritus. 
Laboratory testing in turn established liver enzyme elevations 
- the diagnosis being liver toxicity secondary to the treatment 
provided. Meglumine antimoniate was therefore withdrawn, 
followed by the antiretroviral therapy - resulting in clinical 
improvement and normalization of the liver enzymes. After 
this period of time, comprising one month of treatment with 
meglumine antimoniate, the patient responded favorably, with 
gradual disappearance of the lesion on the cheek mucosa. 
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CASE 1 CASE 2 CASE 3 
AGE 70 years 41 years 50 years 
SEX Male Male Male 
LOCATION Floor of mouth Cheek mucosa 
Upper alveolar ridge, 
affecting palatal and 
vestibular aspects 
SIZE 
(greater diameter) 2 cm 3 cm 5 cm 
CLINICAL PICTURE
Indurated, painful 





Bleeding and painful 
granulomatous, excrescent 
lesion




corticotherapy, DVT and 
relapsing 
orchiepididymitis 
Ex-IVDA, HCV+, TBC 




Abdominal ultrasound (-), 
culture (-), bone marrow 
biopsy (-), Leishmania 
IgG (+), hematimetry (-) 
Abdominal ultrasound (-), 
bone marrow biopsy (-) ------------------
TREATMENT
Meglumine antimoniate, 
20 mg/kg/day, during 28 
days 
Meglumine antimoniate, 
20 mg/kg/day, during 28 
days. HAART ------------------
SIDE EFFECTS OF 
TREATMENT                   No 
Yes
Vomiting, asthenia, 
anorexia, febrile sensation 
and pruritus 
------------------- 
            COURSE
Healing after treatment, 
without signs of relapse 
after 10 years of follow-up 
Healing after treatment, 
without signs of relapse 
after 1 year of follow-up ------------------
Fig. 2. Case 3: excrescent lesion of granulomatous appearance 
affecting the maxillary alveolar ridge, including the vestibular 
and palatal aspects.
Fig. 1. Case 2: Left: clinical appearance of the patient, showing swelling 
of the right side of the face. Right: ulceration of the cheek mucosa with 
white plaques attributable to Candida albicans overinfection.
DM= diabetes mellitus; DVT= deep venous thrombosis; IVDA= intravenous drug abuser; TBC= tuberculosis; HCV= hepatitis C 
virus; HAART= highly active antiretroviral therapy. 
table 1. Patient characteristics, treatment and course.
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One month after the end of treatment with meglumine an-
timoniate, secondary prophylaxis was started with aromatic 
diamidines (pentamidine isethionate) every 15 days (4 mg/kg 
b.w.), and maintained on occasion of the last control. One 
year after the end on treatment with meglumine antimoniate, 
no evidence of relapse was observed.
Case 3. A 50-year-old male presented with a two-month 
lesion located in the maxillary alveolar ridge region exten-
ding from tooth 17 to 22, and affecting both the vestibular 
aspect and the palatal surface - with a maximum diameter 
of 5 cm. The lesion was excrescent, granulomatous, hemo-
rrhagic and painful (Fig. 2). The patient presented no other 
clinical manifestations. The personal history comprised HIV 
infection, hemophilia and surgery for a duodenal ulcer. The 
histological study of a biopsy of the oral lesion indicated 
leishmaniasis (Fig. 3). The patient left the hospital after 
diagnosis, without receiving treatment, and the subsequent 
course is not known.
DIsCUssION
Mucosal involvement due to New World Leishmania species 
(L. braziliensis) is observed in 1-10% of cases, generally 
developing 1-5 years after the healing of cutaneous leishma-
niasis, though in some cases mucosal and skin lesions can 
coincide (8,9). Approximately 90% of these patients present 
a prior cutaneous scar (8,9). Occasionally, the mucosal lesio-
ns may also appear in patients with no previous skin lesions 
(9). Mucosal leishmaniasis usually starts as erythema and 
ulceration, generally in the nasal fossa, and evolves towards 
perforation of the septum and a destructive inflammatory 
lesion. Mucosal disease caused by L. braziliensis occasio-
nally has been described outside Latin America, and can 
be acquired by traveling persons (8).
Infection due to L. infantum is found in Southern Europe, North 
Africa, the Middle East, Pakistan and China. In the Mediterra-
nean, the parasite can cause VL, CL, as well as localized mucosal 
leishmaniasis. Aliaga et al. reviewed localized mucosal leishma-
niasis caused by L. infantum in a total of 31 cases (12). 
The authors consider a patient to have localized mucosal 
leishmaniasis secondary to L. infantum when the following 
criteria are met: 1) acquisition of the disease in areas that are 
endemic for L. infantum; 2) identification of the parasite in 
the oral mucosa biopsy (both tissue staining and culture); 
3) absence of the parasite (visualization or culture) in bone 
marrow aspirate (or in liver or spleen aspirate); and 4) no 
clinical evidence of  visceral or cutaneous leishmaniasis 
(12). Our first two patients meet all the criteria for localized 
mucosal leishmaniasis due to L. infantum. The third case 
would have required a bone marrow aspirate, for example, 
to discard the presence of Leishmania in other locations. Of 
the cases reviewed by Aliaga et al. (12), 90% corresponded 
to males. The mean age was 48 ± 14 years. Fourteen cases 
were documented in Spain (45.16%), 9 in Italy (29%), 4 in 
France (12.9%), 2 in England (6.45%), and one case each 
in Morocco and the United States (3.22%). Seven of the 
patients (22.58%) showed HIV coinfection (12). All three 
of our patients were men, with a mean age of 53.6 years. All 
three were Spaniards living in Spain, and none had recently 
traveled abroad. Two of them (66.6%) had HIV coinfection, 
and the third was receiving immune suppressive therapy in 
the form of corticoids.
In the review published by Aliaga et al. (12), lesions are 
described in the mucosa of the nose, cheek, lips, soft pala-
te, hard palate, tongue, tonsils and larynx. The lesions are 
generally red or purple in color and manifest as a nodule, 
tumor, polypoid lesion or granular inflammation. Ulcera-
tions can be found on the tongue, tonsils, lips, palate and 
vocal cords. The lesions were painless in all patients except 
two (12). In our series the lesions were located on the cheek 
mucosa, the floor of the mouth and maxillary mucosa. In 
two cases the lesions manifested as ulcers, while the third 
patient presented a granulomatous tumefaction. The lesions 
were painful in all three cases.
Mediterranean mucosal leishmaniasis shows numerous 
differences with respect to mucosal leishmaniasis caused 
by L. braziliensis. In the latter presentation of the disease, 
Fig. 3. Histopathology of case 3: Left: hematoxylin-eosin staining, x100. Mucosa of the oral cavity showing abundant 
macrophages loaded with Leishmania protozoa, together with an epithelium showing no alterations. Right: periodic 
acid of Schiff  (PAS) staining, x100. Mucosa of the oral cavity, showing abundant intensely stained Leishmania 
parasites in the cytoplasm of the macrophages.
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the nasal cavity is affected in 90% of cases, while in muco-
sal leishmaniasis in Mediterranean countries such lesions 
are found in only 16% of cases, approximately. Moreover, 
Mediterranean mucosal leishmaniasis has a better prognosis 
than mucosal leishmaniasis in South America. The number 
of parasites found in the lesions of mucosal leishmaniasis 
caused by L. braziliensis is limited, while the parasite burden 
found in lesions of Mediterranean mucosal leishmaniasis 
is important (12).
The incidence of leishmaniasis as an opportunistic disease 
has increased in recent years due to the growing number 
of  patients with immune depression secondary to chro-
nic illnesses, neoplasms, transplants, immunosuppressive 
treatments, and HIV infection (1-3,5,6). In patients with 
HIV, Leishmania infection is not very common, though it 
is believed that 50% of adult patients with visceral leishma-
niasis are HIV-positive (3). Although the transmission of 
leishmaniasis in patients coinfected with HIV most often 
occurs via the mosquito vector, there have been reports of 
alternative routes of transmission, likewise shared by HIV, 
such as parenteral inoculation (intravenous drug abusers 
who share needles, blood transfusions, laboratory accidents, 
etc.), sexual transmission, organ transplantation, and ver-
tical (trans-placental) transmission (1-5,8,9). The World 
Health Organization (WHO) estimates that 2-3% of AIDS 
patients in Southeast Europe have developed this opportu-
nistic infection (2). Leishmaniasis can manifest in any stage 
of HIV infection, though the diagnosis typically coincides 
with periods of  marked host immune depression. Some 
authors consider that this may be due to the lymphopenia 
induced by leishmaniasis itself  (2,3).
The differential diagnosis of  oral mucosal leishmaniasis 
must be established with fungal infections (blastomyco-
sis), syphilis, tuberculosis, leprosy, sarcoidosis, midline 
granuloma, Wegener’s disease and neoplasms, among other 
disorders (13,14).
The treatment of choice in all clinical forms of leishmaniasis 
is based on the administration of pentavalent antimonial 
drugs such as meglumine antimoniate (Glucantime®) and 
sodium stibogluconate (Pentostam®). The former drug 
is more widely used, preferentially via the intramuscular 
route - with intravenous dosing as secondary alternative 
(3,5,9,12,15). The meglumine antimoniate dosage recom-
mended by the United States Centers for Disease Control 
(CDC) and the WHO is 20 mg/kg b.w./day, via the intramus-
cular or intravenous route, to a maximum of 850 mg/day 
(to avoid side effects), for at least 20 days - with extension 
during at least two weeks beyond apparent parasitological 
healing (2,9,15). Mediterranean mucosal leishmaniasis 
should be treated for 28 days, though shorter therapies may 
also be appropriate (12). The possible adverse effects of these 
drugs are: myalgia, joint pain, anorexia, nausea, vomiting, 
headache, electrocardiographic changes (T-wave inversion, 
prolongation of  the QT interval), hypertransaminemia, 
chemical pancreatitis, thrombocytopenia and neutropenia 
(5,9,15,16). As an alternative to such treatment, patients can 
be prescribed amphotericin B, pentamidine, rifampicin or 
ketoconazole (2,9,12,15,17). Other drugs that have been used 
for treatment are: phenothiazines, paromomycin, allopuri-
nol, itraconazole, cyclosporine, miltefosin, dapsone, ami-
nosidine and interferon (2,9,12,15,16). Other management 
options include surgery, topical treatments, immunotherapy, 
and infrared heat (2,6,9,12). In patients with Leishmania and 
HIV coinfection, the same management protocol is applied, 
though some authors recommend life-long prophylaxis with 
aromatic diamidines (Pentamidina®) in aerosol, to avoid 
relapses (5). Our first two cases were treated with meglu-
mine antimoniate (Glucantime®) 20 mg/kg/day, during one 
month. In the second case, and following initial treatment, 
secondary prophylaxis was provided in the form of aromatic 
diamidines (Pentamidina®) every 15 days (4 mg/kg b.w.). 
The third patient received no treatment, since he left the 
hospital following diagnosis of the disease.
Our first two patients were seen to be free of disease after 
one and 10 years of follow-up, respectively.
CONCLUsIONs
The incidence of leishmaniasis as an opportunistic disea-
se has increased, due to the growing number of immune 
depressed patients. As a result, leishmaniasis of the oral 
mucosa must be considered in the differential diagnosis 
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